Q-omics provides the consensus-scored TLK2P2 profile across patient tissues and cancer cell-line models. TLK2P2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TLK2P2 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TLK2P2 RNA expression shows 18,799 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, KIRC, and THYM as cancer lineages where TLK2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLK2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLK2P2 survival associations across molecular data types. TLK2P2 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLK2P2 RNA expression–survival associations across cancer types. High TLK2P2 expression shows unfavorable associations in COAD and THCA, but favorable associations in BRCA, UCS, BLCA and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BRCA as the clearest survival context for TLK2P2 RNA expression.
This table summarizes TLK2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TLK2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLK2P2 shows higher tumor expression in KIRC, COAD, KIRP, LIHC, CHOL and STAD. The KIRC box plot shows higher TLK2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.176, t-test p < 0.001).
This table shows molecular features associated with TLK2P2 in patient tissues and cancer cell lines. In patient samples, TLK2P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
